🇺🇸 FDA
Pipeline program

IMP Placebo, Comparator Placebo, Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension., CHF5993 pMDI (100) -152a

CLI-05993AA5-06

Phase 3 small_molecule active

Quick answer

IMP Placebo, Comparator Placebo, Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension., CHF5993 pMDI (100) -152a for Uncontrolled Asthma is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A
Indication
Uncontrolled Asthma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials